The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
Assessment of 18 azotaemic patients treated with long-term 1alpha-hydroxyvitamin D3 (1alpha-OHD3) confirms the generally favourable effect of this analogue of 1,25-dihydroxyvitamin D3 in azotaemic osteodystrophy. Growing children with radiological rickets respond very well as do adults showing mild hyperparathyroidism with or without osteomalacia. However, patients with severe 'pure' hyperparathyroidism and features of autonomy do not respond well and in such patients 1alpha-OHD3 alone should be avoided. Phosphate restriction and occasionally a sub-total parathyroidectomy may be indicated in these patients.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D002648:Child; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D007085:Ilium / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010002:Osteitis Fibrosa Cystica / Q000473:pathology; D010018:Osteomalacia / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood; D014511:Uremia / Q000188:drug therapy
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D000469:Alkaline Phosphatase; D002118:Calcium